VALBIOTIS
14.12.2022 17:41:37 CET | Business Wire | Press release
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the signature of a research partnership in intestinal microbiota with the MEDIS2 Unit from the Clermont Auvergne University on its active substances TOTUM•070 and TOTUM•448 against dyslipidemia and metabolic liver disease, partly financed by the French National Research Agency. Led by a laboratory shared by the two entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will provide exclusive data on the effects and modes of action of Valbiotis' plant-based substances at the intestinal level, in the context of non-drug strategies to combat metabolic and cardiovascular diseases.
Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Board of Directors at Valbiotis states: "In research and development, our public-private partnership strategy is based on collaborations with high scientific added value. The in vitro digestive model project led by the MEDIS Unit is a unique innovation in human digestion research, which we have been following for a long time and to which we are very happy to contribute within this new joint laboratory. As an industrial player, the MIMETiv project represents for us a very promising lever to approach cardiovascular and metabolic diseases from a digestive and intestinal perspective, with a particular focus on the intestinal microbiota. This is an innovative angle, in line with our research and development strategy. At the end of this project, we should obtain exclusive data for our active substances in two of our key indications: dyslipidemia and metabolic liver disease."
Stéphanie BLANQUET-DIOT, Professor and Deputy Director of MEDIS, comments: "This in vitro digestive system is unique in the number of parameters reproduced in relation to in vivo digestion in humans, such as body temperature, pH kinetics in the stomach and small intestine, gastrointestinal transit time, differential gastric emptying between liquids and solid particles, salivary, gastric, biliary and pancreatic secretions, absorption of water and digestive products, progressive anaerobics along the digestive tract and microbiota in small intestine-reproducing compartments."
Dyslipidemia and metabolic liver disease (NAFL, NASH), the respective indications for the active substances TOTUM•070 and TOTUM•448, are highly prevalent diseases, precursors to pathologies that are life-threatening for patients (atherosclerosis, cirrhosis). Their complex pathophysiology includes, among other aspects, alterations in carbohydrate and/or lipid metabolism, digestive abnormalities and disturbances of the intestinal microbiota, all of which the MIMETiv project will be able to approach in humans in an integrated manner. Among the main innovations, MIMETiv should provide access to the microbiota of the small intestine, the major site of digestion and absorption of dietary carbohydrates and lipids in humans. To date, data linking metabolic diseases and gut microbiota have mainly been obtained from stool analysis, which partially reflects the microbiota of the colon (large intestine).
The MIMETiv project: an exclusive tool for R&D on metabolic and cardiovascular diseases
The MIMETiv project, which will benefit from the combined expertise of the MEDIS Unit and Valbiotis, will take place in two stages.
The first will lead to the design of the world's most complete model of the human digestive environment in 2024, based on the long-standing in vitro simulation work of the MEDIS Unit. The work will consist in optimizing the ESIN (Engineered Stomach and Small Intestine) system, developed by MEDIS, by improving its performance and integrating the human microbiota in key compartments of the digestive tract such as the small intestine.
Once validated, this model will constitute a proprietary tool for the evaluation of Valbiotis' plant-based active substances in the human digestive environment. The explorations performed will cover a complete set of R&D objectives for two active substances, TOTUM•070 and TOTUM•448:
- metabolomic analysis, to identify the metabolites of these active substances and to specify their bioavailability in the different gastrointestinal compartments;
- analysis of modes of action, to evaluate their effects on digestion and intestinal absorption of lipids and carbohydrates;
- analysis of the intestinal microbiota, to evaluate their impact on dysbiosis associated with metabolic diseases;
- analysis of hepatic metabolic pathways, thanks to the original coupling of ESINs with liver cells in culture, to assess their possible modulation by Valbiotis' active substances.
The Management Committee of the MIMETiv joint laboratory is composed of 5 members. It is co-led by Stéphanie BLANQUET-DIOT, Deputy Director of MEDIS, in charge of the digestive environment simulation platform, with strong expertise in microbiology and intestinal microbiota, in vitro digestion, digestive physiology and nutrition, and Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Valbiotis Board of Directors. He is responsible for the R&D platform in Riom, with extensive expertise in metabolic diseases and the development of plant-based health products.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022 and completed by an amendment on November 8, 2022. This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1MIMETiv: Microbiote intestinal et maladies métaboliques chez l’Homme (Intestinal microbiota and metabolic diseases in humans): a unique in vitro digestive system to catalyze the development of innovative nutritional strategies.
LabCom Scientific document.
2The MEDIS Unit (Microbiologie Environnement Digestif et Santé: Microbiology Digestive Environment and Health) is a Joint Research Unit between INRAE (Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement: National Research Institute for Agriculture, Food and the Environment) and UCA (Clermont Auvergne University) created in January 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 10:00:00 CET | Press release
Twilio Segment gives Chelsea a more connected view of its global fanbase for real-time responses to personal interests and match moments on the pitch Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to t
EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 09:49:00 CET | Press release
Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI
Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 09:43:00 CET | Press release
Expanding Alipay+'s national QR scheme connections to 16, spanning Asia, the Middle East and Latin AmericaEnabling international travellers to pay with home wallets at Pix merchants across Brazil, supporting local businesses and inbound tourism Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloadi
Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release
New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
